share_log

Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs...

Merit MedicalはEndoGastric Solutionsとの資産買収契約を締結し、現金総額約1.05億ドルで取引を行いました。EPSのFY24年度の財務ガイダンスを3.22〜3.31に更新し、売上高の見通しを13.2億〜13.4億ドルに引き上げました。つきましては、3.28〜3.35ドルから3.33ドルの推定値に対して3.22〜3.31ドルとなります。

Benzinga ·  07/01 09:19

Merit Medical Executed An Asset Purchase Agreement With EndoGastric Solutions For A Total Cash Consideration Of ~$105M; Updates FY24 Financial Guidance EPS From $3.28-$3.35 To 3.22-$3.31 Vs $3.33 Est.; Revenue From $1.31B-$1.325B To $1.32B-$1.34B Vs $1.32B Est.

  • Asset acquisition expands Merit's endoscopy portfolio with a minimally invasive solution for patients suffering from chronic gastroesophageal reflux disease (GERD).
  • Asset acquisition projected to add approximately $30 million of revenue, on an annualized basis, in key gastrointestinal endoscopy market that leverages existing commercial footprint.
  • Merit reaffirms full-year 2024 financial guidance on standalone basis and updates full-year 2024 financial guidance to include projected partial-year impact from this acquisition.

SOUTH JORDAN, Utah...

これらの内容は、情報提供及び投資家教育のためのものであり、いかなる個別株や投資方法を推奨するものではありません。 更に詳しい情報
    コメントする